Actively Recruiting
Impact of Early Lung Physiology, Viral Infections and the Microbiota on the Development and Progression of Lung Disease in Children With Cystic Fibrosis
Led by Insel Gruppe AG, University Hospital Bern · Updated on 2020-11-04
500
Participants Needed
1
Research Sites
2061 weeks
Total Duration
On this page
Sponsors
I
Insel Gruppe AG, University Hospital Bern
Lead Sponsor
U
University Children's Hospital, Zurich
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study collects data on microbiological factors and lung function parameters (e.g. spirometry, body plethysmography, lung-MRI) to assess their interaction on the lung growth and lung development of infants and children with Cystic Fibrosis (CF).
CONDITIONS
Official Title
Impact of Early Lung Physiology, Viral Infections and the Microbiota on the Development and Progression of Lung Disease in Children With Cystic Fibrosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Infants with a confirmed diagnosis of CF by newborn screening
- Age 18 years or younger
- Written informed consent by patient and/or parent
You will not qualify if you...
- Need for respiratory support for more than three days
- Severe malformations or known diseases other than cystic fibrosis
- Maternal drug abuse
- Known severe maternal disease
- Severe problems of communication
- Pacemaker or continuous glucose monitor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Children's Hospital Bern
Bern, Switzerland, 3010
Actively Recruiting
Research Team
P
Philipp Latzin, MD PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here